Swedish Ibrance Registries Insights (SIRI)

Recruiting now

Conditions studied: Malignant Neoplasm of Breast

In brief

The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.

Key facts

Study ID

NCT04654208

Run by

Pfizer

People needed

1500

Starts

2020-12-15

Expected to finish

2026-05-31

Last updated by the study team

2026-03-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
• One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)
• Age ≥18 years at index date

You may not qualify if…

• There are no exclusion criteria

Where it is running

• Pfizer Sweden — Sollentuna, Sweden (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.